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Introduction
Due to increasing resistance, alternatives to mupirocin
and chlorhexidine for decolonization of MRSA carriage
need to be evaluated.
Objectives
To evaluate the efficacy of polyhexanide (Prontoderm®)
vs placebo in eliminating MRSA carriage at day 28
(D28) after the end of treatment.
Methods
In a 1,900-bed teaching hospital, MRSA-colonized
patients were randomized into a double-blind, placebo-
controlled superiority trial. Patients were treated with
either polyhexanide (antiseptic and surface-active sub-
stances; group I) or placebo (only surface-active sub-
stances; group P) applied to the anterior nares and skin
for 10 days. The primary outcome was MRSA decoloni-
zation at D28 assessed by both intention-to-treat ([ITT]
responder analysis) and per-protocol (PP) analysis
(microbiological follow-up ± 7 days and topical treat-
ment ≥ 5 days). Secondary outcomes included MRSA
decolonization according to nasal MRSA carriage, safety
and emergence of resistance.
Results
Of 2590 patients screened, 146 patients (group I, 71;
group P, 75) were randomized between January 2011
and July 2014. Primary outcome was missing for 11
(7.5%) patients. ITT analysis showed that 24/71 (33.8%)
patients in group I vs 22/75 (29.3%) in group P were
MRSA-free at D28 (risk difference, 4.5%; 95% CI, -10.6%
to 19.5%; P=0.56). PP analysis confirmed the results
with 19/53 (35.8%) decolonized polyhexanide-treated
patients vs 17/56 (30.4%) in the placebo arm (risk differ-
ence, 5.5%; 95% CI, -12.2% to 23.0%; P=0.54). In the
subgroup of MRSA nasal carriers, PP analysis showed
that 6/15 (40.0%) patients in group I vs 2/11 (18.2%) in
group P were decolonized (P=0.40). Nine serious
adverse events occurred in group I vs 12 in group P;
none was attributable to study medication. Emergence
of polyhexanide resistance was not observed.
Conclusion
This study suggests that under real-life conditions a sin-
gle polyhexanide decolonization course is marginally
effective in eradicating MRSA carriage.
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